Accelerated Early Drug Development: Compressing the Timeline from Clinical to Commercial

The age of advanced therapeutics (eg, gene therapy, orphan, etc) is characterized by accelerated development programs for personal/targeted medicines. An increased focus on smaller, more well-defined patient populations offers more biotechs a realistic option to go to market on their own. Most significantly, increasingly rapid approval pathways available for breakthrough therapies mean the progression from early to late stage can be quicker than in the past, highlighting the greater role of clinical/med affairs/commercial teams to start setting strategies and plans earlier in the process.

Join our panelists as they discuss the implications of this fundamental change, and share their perspectives on how companies are responding to them in practical terms - from in- to -out-licensing and building new companies to creating a value proposition and implementing commercial strategies in earlier phases of development.

MODERATOR
Jason McDonough, PhD
SVP, Medical Strategy, Cello Health

PANELISTS
Jen King
SVP, BD Intellia Therapeutics

Nerissa C. Kreher, MD, MBA
Chief Medical Officer, AVROBIO

Robert Ward
CEO, Eloxx Pharmaceuticals

Ed Saltzman
Chairman, Defined Health, a Cello Health business

The views and opinions expressed by the panelists are their own and may not represent the views of their respective companies or employers.